Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S. Tonyali O, et al. Among authors: sener n. Onkologie. 2013;36(10):554-8. doi: 10.1159/000355156. Epub 2013 Sep 16. Onkologie. 2013. PMID: 24107908
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, Ozdemir NY, Yazilitas D, Benekli M, Uner A, Yamac D, Demirci U, Yildiz R, Karaca H, Unal OU, Bal O, Gumus M, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: sener n. J Cancer Res Clin Oncol. 2012 Dec;138(12):2145-51. doi: 10.1007/s00432-012-1296-x. Epub 2012 Aug 10. J Cancer Res Clin Oncol. 2012. PMID: 22878681
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.
Korkmaz T, Seber S, Kefeli U, Sari E, Canhoroz M, Oven B, Yildirim E, Yasar N, Aydin D, Balvan O, Sener N, Yuksel S, Mert A, Polat O, Yumuk F, Kanat O, Gumus M, Turhal NS. Korkmaz T, et al. Among authors: sener n. Clin Transl Oncol. 2013 Jul;15(7):535-40. doi: 10.1007/s12094-012-0960-6. Epub 2012 Nov 10. Clin Transl Oncol. 2013. PMID: 23143955
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, Dayan A, Demir L, Geredeli C, Kocer M, Arslan UY, Inal A, Akman T, Coskun U, Sener N, Inanc M, Elkiran ET, Ozdemir NY, Durnalı AG, Suner A, Alici S, Tarhan MO, Boruban C, Oksuzoglu B, Urakci Z. Kaplan MA, et al. Among authors: sener n. Breast Cancer. 2014 Nov;21(6):677-83. doi: 10.1007/s12282-013-0441-y. Epub 2013 Jan 19. Breast Cancer. 2014. PMID: 23335064 Clinical Trial.
Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.
Uyeturk U, Oksuzoglu B, Akman T, Turker I, Sener N, Tastekin D, Bal O, Berk V, Arslan UY, Urakci Z, Bilir C, Yilmaz U, Yazilitas D, Ulas A, Sonmez OU, Budakoglu B, Cihan S, Uysal M. Uyeturk U, et al. Among authors: sener n. Med Oncol. 2014 Apr;31(4):929. doi: 10.1007/s12032-014-0929-0. Epub 2014 Mar 22. Med Oncol. 2014. PMID: 24659267
Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.
Aydin D, Sendur MA, Kefeli U, Ustaalioglu BB, Aydin O, Yildirim E, Isik D, Ozcelik M, Surmeli H, Oyman A, Isik S, Sener N, Ercelep O, Odabas H, Aliustaoglu M, Gumus M. Aydin D, et al. Among authors: sener n. Clin Colorectal Cancer. 2017 Mar;16(1):78-83. doi: 10.1016/j.clcc.2016.04.013. Epub 2016 May 7. Clin Colorectal Cancer. 2017. PMID: 27247089
Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study.
Olmez OF, Bilici A, Er O, Bisgin A, Sevinc A, Akman T, Uslu R, Mandel NM, Yalcin S, Teomete M, Gorumlu G, Demir A, Namal E, Alici S, Selcukbiricik F, Bavbek S, Paksoy F, Basaran G, Ozer L, Sener N, Harputluoglu H; TUMPACT Study Group. Olmez OF, et al. Among authors: sener n. Jpn J Clin Oncol. 2024 May 7;54(5):562-568. doi: 10.1093/jjco/hyae002. Jpn J Clin Oncol. 2024. PMID: 38271177
98 results